Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 19, 2022

High-Dose Osimertinib in Patients With Advanced-Stage EGFR Exon 20 Mutation–Positive NSCLC

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
Lung Cancer 2022 Jun 23;170(xx)133-140, F Zwierenga, B van Veggel, LEL Hendriks, TJN Hiltermann, BI Hiddinga, LBM Hijmering Kappelle, A Ter Elst, SMS Hashemi, AC Dingemans, C van der Leest, AJ de Langen, MM van den Heuvel, AJ van der Wekken

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading